Is REGN a Buy? What to Consider in 2026
Short answer
The bull case for Regeneron Pharmaceuticals (REGN) rests on Dupixent keeps compounding: Dupixent remains the central growth driver, with global net sales rising about 31% to roughly $4.9 billion in Q1 2026 and label expansions into conditions like COPD and chronic spontaneous urticaria widening the addressable population. Total revenue (TTM, approx) is ~$14 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The clearest risk is Eylea biosimilar erosion. Whether REGN is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base. Regeneron was founded in 1988 by Leonard Schleifer, who remains a central leader, with chief scientific officer George Yancopoulos shaping its science-first culture. The company built its reputation on proprietary VelociSuite antibody-discovery technologies and the Regeneron Genetics Center, an internal engine that turns large-scale human genetics into drug targets. That R&D productivity, rather than acquisitions, has historically driven its growth. In 2025 the board initiated its first quarterly dividend and expanded share repurchases, signaling a more mature capital-return posture alongside heavy ongoing R&D investment.
What's the case for buying REGN?
Dupixent keeps compounding
Dupixent remains the central growth driver, with global net sales rising about 31% to roughly $4.9 billion in Q1 2026 and label expansions into conditions like COPD and chronic spontaneous urticaria widening the addressable population. Because Regeneron splits economics with Sanofi, growth flows through as rising collaboration revenue. As long as new indications and geographies keep landing, this franchise can offset pressure elsewhere in the portfolio.
A deep, diversified pipeline
Regeneron carries nearly 50 clinical candidates across roughly six therapeutic areas, including hematology-oncology, complement-mediated diseases, and anticoagulation. The company also logged its first gene therapy approval, signaling expansion beyond antibodies. This breadth means the investment case does not rest on any single readout, though individual trials still carry binary outcomes.
R&D productivity as a moat
The VelociSuite platform and Regeneron Genetics Center give the company an internal discovery engine that has repeatedly produced approved medicines without relying on large acquisitions. Planned R&D investment of roughly $6.6 billion in 2026 reflects management's bet that this engine keeps generating the next franchises. Investors who value durable innovation tend to anchor on this capability rather than any one drug.
Oncology optionality
Libtayo anchors a growing oncology effort, with fianlimab and other programs advancing in late-stage development. Oncology could become a third major pillar alongside immunology and eye disease over time. It is earlier in its revenue contribution, so it represents upside optionality more than a current cash driver.
What are the risks to REGN?
The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics.
How is REGN valued? (as of June 27, 2026)
- Total revenue (TTM, approx): ~$14 billion
- Q1 2026 total revenue: ~$3.6 billion (up ~19% YoY)
- Dupixent global net sales (Q1 2026): ~$4.9 billion (up ~31%)
- Eylea + Eylea HD U.S. net sales (Q1 2026): ~$941 million combined
- Cash and marketable securities (approx): ~$17 billion
- P/E (approx): ~15x
- Market capitalization (approx): ~$66 billion
Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron reported about 19% revenue growth and adjusted EPS of roughly $9.47 in Q1 2026, beating estimates, and authorized an additional $3 billion buyback. The mid-teens P/E reflects the market weighing strong Dupixent growth against expected Eylea biosimilar erosion.
How do you decide if REGN is a buy?
Rather than asking whether REGN is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold REGN indirectly through an index or sector ETF before adding more.
For the full picture, see the REGN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about REGN against your real portfolio and see your actual exposure before deciding.
The bottom line on REGN
The bottom line: Regeneron Pharmaceuticals's story right now is Dupixent keeps compounding, with total revenue (ttm, approx) at ~$14 billion. If you believe that narrative continues, the call is about sizing REGN sensibly and checking overlap with what you own; if you doubt it (the risk: the clearest risk is Eylea biosimilar erosion.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around REGN with Walnut
Use Regeneron Pharmaceuticals as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is REGN a good stock to buy right now?
+
The case for Regeneron Pharmaceuticals right now is Dupixent keeps compounding, with total revenue (ttm, approx) at ~$14 billion. If you believe that thesis holds, REGN is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the clearest risk is Eylea biosimilar erosion. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Regeneron Pharmaceuticals do?
+
Regeneron makes money primarily through two large franchises.
What are the main risks of REGN?
+
The clearest risk is Eylea biosimilar erosion. Amgen's Pavblu launched in late 2024 and pressured sales, and settlements clear paths for Sandoz, and Alvotech and Teva, to launch competing copies in the U.S. around the fourth quarter of 2026, with erosion expected to accelerate. Eylea HD and Dupixent growth are the offsets, but the timing gap matters. The business is also concentrated in a few franchises, so a single setback in Dupixent or a major pipeline failure would weigh heavily, and the collaboration structure with Sanofi means Regeneron does not control all of its largest product's economics.
Is REGN a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is Dupixent growth plus a productive R&D engine and deep pipeline. The bear case is accelerating Eylea biosimilar erosion and franchise concentration. A long-term investor comfortable with biotech volatility weighs those differently than someone needing near-term stability. Consider how REGN fits your overall portfolio and existing healthcare exposure.
What does Regeneron do?
+
Regeneron is a biotechnology company that discovers, develops, and sells medicines. Its largest products are Dupixent for inflammatory diseases such as eczema and asthma (partnered with Sanofi), and Eylea and Eylea HD for retinal eye diseases. It also markets Libtayo in oncology and runs a broad pipeline built on its VelociSuite discovery platform and the Regeneron Genetics Center.
Does REGN pay a dividend?
+
Yes. Regeneron initiated its first quarterly cash dividend in 2025, declaring $0.88 per share, alongside expanded share repurchases. The dividend yield is small, roughly half a percent, so REGN is primarily a growth-oriented holding rather than an income stock. Most of its shareholder return historically came through buybacks and share-price appreciation rather than dividend payments.
What is Regeneron's biggest drug?
+
Dupixent is Regeneron's biggest and fastest-growing franchise. Global net sales reached about $4.9 billion in Q1 2026, up roughly 31% year over year, driven by expanding approvals across eczema, asthma, COPD, and other inflammatory conditions. Because it is developed with Sanofi, Regeneron records its share as Sanofi collaboration revenue rather than direct product sales.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell REGN; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.